Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUENTIAL: VD Intensification in Relapsed/Refractory Multiple Myeloma
NCT00908232Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2008
- Primary completion
- Aug 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 10
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started May 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00908232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00908232.